Milvexian

Johnson & Johnson (Janssen) · Bristol Myers Squibb · JNJ-70033093 · BMS-986177

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
17 in total · 4 in the EU
Targets
 

What this is

How it works
Factor XIa inhibitor
Tested for
Ischemic Stroke; Ischemic Attack, Transient, Atrial Fibrillation
Main trialPhase 3
“The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.”In the company’s words, NCT05702034 on ClinicalTrials.gov
Other names
JNJ-70033093 · BMS-986177

Other drugs for Ischemic Stroke; Ischemic Attack, Transient

All 45 drugs for Ischemic Stroke; Ischemic Attack, Transient

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials17

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 15 Oct 2026 A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Phase 3Active, not recruiting 8 Dec 2026 A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
Phase 3Completed 6 Feb 2026 A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
Phase 2Completed 6 Apr 2021 A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery
Phase 2Completed 31 Mar 2022 A Study on BMS-986177 for the Prevention of a Stroke in Patients Receiving Aspirin and Clopidogrel
Phase 1Completed 4 Mar 2018 Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment
Phase 1Completed 19 Feb 2019 A Study to Assess Administration of an Oral Anti-thrombotic With Antiplatelet Therapy in Healthy Subjects
Phase 1Completed 8 Apr 2020 A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
Phase 1Completed 14 Nov 2020 A Study of JNJ-70033093 in Healthy Participants
Phase 1Completed 9 Jun 2021 A Study of JNJ-70033093 and Digoxin in Healthy Participants
Phase 1Completed 22 Aug 2021 A Study of Milvexian Using an IV Microtracer With Additional Formulation and Food Effect Comparison in Healthy Participants
Phase 1Completed 25 Oct 2021 A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants
Phase 1Completed 4 Dec 2021 A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants
Phase 1Completed 6 May 2022 A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants
Phase 1Completed 7 Jun 2023 A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants
Phase 1Completed 20 Jul 2023 A Study of Milvexian in Healthy Adult Females
Phase 1Authorised not given Open-label, Multi-center, Single-dose Phase 1 Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Milvexian in Pediatric Patients From 28 Days to Less Than 18 Years of Age at Risk of Thromboembolic Events
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Milvexian

Following is part of Solo: you see every change to Milvexian the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in